AR109081A1 - PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS - Google Patents
PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONSInfo
- Publication number
- AR109081A1 AR109081A1 ARP170101994A ARP170101994A AR109081A1 AR 109081 A1 AR109081 A1 AR 109081A1 AR P170101994 A ARP170101994 A AR P170101994A AR P170101994 A ARP170101994 A AR P170101994A AR 109081 A1 AR109081 A1 AR 109081A1
- Authority
- AR
- Argentina
- Prior art keywords
- testosterone undecanoate
- formulations
- incorporated
- proliposomal
- replacement therapy
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen formulaciones de undecanoato de testosterona (TU) en las que se incorpora TU en dispersiones de polvo proliposomales de TU y distearoil fosfatidilcolina (DSPC). Las dispersiones de polvo proliposomales también se pueden combinar con excipientes farmacéuticamente aceptables, e incorporarse en formas de dosificación oral con recubrimiento entérico que son útiles para la terapia de reemplazo de testosterona. Reivindicación 12: Un método de terapia de reemplazo de testosterona (TRT) para un individuo que lo necesita, que comprende: la administración de una forma de dosificación oral de acuerdo con cualquiera de las reivindicaciones 3 - 11, donde eficacia clínica de la forma de dosificación es independiente de los efectos de la alimentación.Testosterone undecanoate (TU) formulations are described in which TU is incorporated into proliposomal powder dispersions of TU and distearoyl phosphatidylcholine (DSPC). Proliposomal powder dispersions can also be combined with pharmaceutically acceptable excipients, and incorporated into enteric coated oral dosage forms that are useful for testosterone replacement therapy. Claim 12: A method of testosterone replacement therapy (TRT) for an individual in need, comprising: administering an oral dosage form according to any one of claims 3-11, wherein clinical efficacy of the form of Dosage is independent of the effects of feeding.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394576P | 2016-09-14 | 2016-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109081A1 true AR109081A1 (en) | 2018-10-24 |
Family
ID=62639461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101994A AR109081A1 (en) | 2016-09-14 | 2017-07-17 | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR109081A1 (en) |
| TW (1) | TW201811336A (en) |
-
2017
- 2017-07-10 TW TW106123064A patent/TW201811336A/en unknown
- 2017-07-17 AR ARP170101994A patent/AR109081A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201811336A (en) | 2018-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019008487A2 (en) | Quinazoline Compound | |
| CO2019000938A2 (en) | Nmda spiro-lactam modulators and methods of use thereof | |
| CO2019015090A2 (en) | Treatment methods for cystic fibrosis | |
| CO2018004776A2 (en) | Therapeutic compositions for the treatment of human immunodeficiency virus | |
| CO2019000941A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| SV2017005601A (en) | PHARMACEUTICAL FORMULATIONS CONTAINING TENOFOVIR AND EMTRICITABINE | |
| CO2019000945A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| CO2019000944A2 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof | |
| CL2018002727A1 (en) | Medicine obtained by combining agonist fxr and arb | |
| CO2019000943A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| PE20150161A1 (en) | USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| CO2018004206A2 (en) | Pharmaceutical formulation for oral administration comprising a compound of 25-hydroxy vitamin d " | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| CR20180228A (en) | ATTACHED THERAPY WITH 25-HYDROXY VITAMIN D AND ARTICLES THEREOF | |
| EA201891575A1 (en) | COMPOSITIONS FOR THE TREATMENT OF URINARY BUBBLE CANCER | |
| SV2017005603A (en) | ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARATION OF THE SAME | |
| MX2018013873A (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer. | |
| ECSP19026973A (en) | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | |
| AR122024A1 (en) | LIPOSOME FORMULATIONS FOR TREATMENT OF CANCERS AND DRUG RESISTANCE OF CANCERS | |
| PH12018502524A1 (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| UY37412A (en) | INDAZOL COMPOUNDS FOR USE IN INJURY OF TENDONS AND / OR LIGAMENTS | |
| AR109081A1 (en) | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS | |
| EA201890929A1 (en) | LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE | |
| CL2019003288A1 (en) | A pharmaceutical combination for the treatment of cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |